HA-966

N/A

Report date: 2022/08/23 20:00:44

Base Information

Drug NameHA-966
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate receptors inhibitors
TargetsGlutamate receptors
Therapy Area/IndicationsPsychotic DisordersAnxiety DisordersParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAventis
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck & Co
Active IndicationsN/A
Inactive IndicationsPsychotic DisordersAnxiety DisordersParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A